CR7622A - Secuencias del control del gen de corina humano - Google Patents

Secuencias del control del gen de corina humano

Info

Publication number
CR7622A
CR7622A CR7622A CR7622A CR7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A CR 7622 A CR7622 A CR 7622A
Authority
CR
Costa Rica
Prior art keywords
corina
gene
control
sequences
human
Prior art date
Application number
CR7622A
Other languages
English (en)
Inventor
Pan Junliang
Wu Quingyu
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of CR7622A publication Critical patent/CR7622A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

S e relaciona con el aislamiento , la clonacion, y la identificacion de las regiones de control de la expresion del gen de corina en mamiferos, incluyendo el promotor y otros elementos reguladores, y el uso de esta region de control de la expresion especifica del corazoon para indentificar nuevos agentes que modulan la expresion de gen de corina y para tratar enfermedades cardiacas.
CR7622A 2002-05-31 2004-12-15 Secuencias del control del gen de corina humano CR7622A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38410802P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
CR7622A true CR7622A (es) 2006-05-29

Family

ID=29711979

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7622A CR7622A (es) 2002-05-31 2004-12-15 Secuencias del control del gen de corina humano

Country Status (18)

Country Link
US (1) US20030223976A1 (es)
EP (1) EP1546172A4 (es)
JP (1) JP2005531302A (es)
KR (1) KR20050009724A (es)
CN (1) CN1671729A (es)
AU (1) AU2003245342A1 (es)
BR (1) BR0311603A (es)
CA (1) CA2487024A1 (es)
CR (1) CR7622A (es)
EC (1) ECSP045518A (es)
IL (1) IL165244A0 (es)
MX (1) MXPA04011944A (es)
NO (1) NO20045722L (es)
PL (1) PL374125A1 (es)
RS (1) RS104404A (es)
RU (1) RU2004139055A (es)
WO (1) WO2003102135A2 (es)
ZA (1) ZA200410400B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
JP2007530016A (ja) * 2004-02-27 2007-11-01 ザ ジェネラル ホスピタル コーポレーション 発毛のための方法および組成物
KR101402636B1 (ko) 2005-12-01 2014-06-03 시바 홀딩 인크 옥심 에스테르 광개시제
WO2010096658A1 (en) 2009-02-19 2010-08-26 The Cleveland Clinic Foundation Corin as a marker for heart failure
CN105734070A (zh) * 2016-04-11 2016-07-06 苏州大学 Corin基因变异体及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917123A (en) * 1997-03-14 1999-06-29 University Of Pittsburgh Transgenic mice containing a nucleic acid encoding tumor necrosis factor-α under the control of a cardiac specific regulatory region
JP4488140B2 (ja) * 1998-06-05 2010-06-23 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト セリンプロテアーゼであるコリン
CA2296792A1 (en) * 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
AU2001243142A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
EP1252300B1 (en) * 2000-02-03 2011-01-19 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
JP2001245671A (ja) * 2000-03-07 2001-09-11 Chiba Prefecture ヒト神経芽細胞腫においてクローニングされた新規遺伝子及び新規遺伝子の断片

Also Published As

Publication number Publication date
ZA200410400B (en) 2006-06-28
EP1546172A4 (en) 2005-11-30
IL165244A0 (en) 2005-12-18
JP2005531302A (ja) 2005-10-20
WO2003102135A3 (en) 2004-11-04
EP1546172A2 (en) 2005-06-29
AU2003245342A1 (en) 2003-12-19
US20030223976A1 (en) 2003-12-04
MXPA04011944A (es) 2005-03-31
WO2003102135A2 (en) 2003-12-11
RS104404A (sr) 2006-12-15
RU2004139055A (ru) 2005-08-20
CN1671729A (zh) 2005-09-21
CA2487024A1 (en) 2003-12-11
ECSP045518A (es) 2005-03-10
KR20050009724A (ko) 2005-01-25
NO20045722L (no) 2004-12-30
PL374125A1 (en) 2005-10-03
BR0311603A (pt) 2005-06-07

Similar Documents

Publication Publication Date Title
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
MX2019007873A (es) Terapia génica para tratar la enfermedad de wilson.
PE20181922A1 (es) Terapia genica para tratar la hemofilia a
MX2021008131A (es) Metodos y composiciones para el tratamiento de la enfermedad de fabry.
PA8804901A1 (es) Inhibicion del receptor para la proteina estimulante del macrofago (ron) y métodos para el tratamiento de lo mismo
AR010348A1 (es) Cetobenzamidas, su utilizacion y composicion farmeceutica que las contienen
UY24805A1 (es) Peptidos y compuestos que se enlazan al receptor de la trombopoyetina
AR126239A1 (es) Región 5’ no traducida y región 3’ no traducida no naturales y uso de estas
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
MX2024005705A (es) Composiciones de liquidos ionicos.
CL2022001185A1 (es) Derivados terapéuticos de interleucina-22
ES2156107T3 (es) Un fgf-4 no glicosilado y composiciones que lo contienen.
HN2003000080A (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos y procedimientos para su uso
DE602005026866D1 (de) Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
IL174525A0 (en) Medicamentously targeted local lipolysis
CR7622A (es) Secuencias del control del gen de corina humano
ES2196313T3 (es) Utilizacion de inhibidores de la actividad del acido retinoico para el tratamiento de pieles sensibles y/o los daños agudos inducidos por las radiaciones uv.
DE60214207D1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
ES2165233T3 (es) Empleo de 1-fosfato de esfingosina, derivados de 1-fosfato de esfingosina y/o sus mezclas para el tratamiento de enfermedades cutaneas inflamatorias.
CL2024003527A1 (es) Composiciones de ruboxistaurina y uso para el tratamiento de enfermedades de la piel.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
AR039803A1 (es) Proteinas 1 y 2 relacionadas con el receptor ldl y tratamiento de los trastornos de huesos o cartilago
DOP2023000132A (es) Composiciones y métodos para tratar la pérdida de audición y/o la pérdida de visión asociada a clrn1
GT199900167A (es) Nuevos bis-benzimidazoles.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)